# Research Loop Progress

## Current Session: h49-h58 (2026-01-31)

### Session Summary

**Agent Role:** Research Executor
**Status:** Completed (8 hypotheses tested)
**Hypotheses Tested:**
- h49: Gene Expression → Drug Mapping Pipeline - **VALIDATED**
- h50: Rare Skin Disease Baseline Evaluation - **VALIDATED**
- h51: Gene Module Similarity for Disease Matching - **INVALIDATED**
- h52: Meta-Confidence Model for Prediction Reliability - **VALIDATED**
- h53: Skin Disease Name Mapping Expansion - **VALIDATED**
- h54: Production Meta-Confidence Pipeline - **VALIDATED**
- h56: Cancer Category Analysis Deep Dive - **VALIDATED**
- h58: 'Other' Category Subcategorization - **VALIDATED**

### CRITICAL DISCOVERY: Gastrointestinal Diseases

**h58 revealed GI diseases have only 5% hit rate** - a severe blind spot.

### Extended Category Performance (16 categories, 5-seed):

| Category | Hit Rate | Priority |
|----------|----------|----------|
| Endocrine | 100.0% | ★★★ High confidence |
| Autoimmune | 92.9% | ★★★ High confidence |
| Dermatological | 88.2% | ★★★ High confidence |
| Psychiatric | 83.3% | ★★★ High confidence |
| Infectious | 75.0% | ★★ Good |
| Respiratory | 71.4% | ★★ Good |
| Cancer | 70.8% | ★★ Good |
| Ophthalmic | 66.7% | ★★ Good |
| Cardiovascular | 62.5% | ★ Average |
| Neurological | 60.0% | ★ Average |
| Other | 57.8% | ★ Average |
| Metabolic | 54.5% | ★ Average |
| Renal | 40.0% | ⚠ Below average |
| Musculoskeletal | 33.3% | ⚠ Below average |
| Hematological | 22.2% | ⚠ Below average |
| **Gastrointestinal** | **5.0%** | ❌ **CRITICAL FAILURE** |

### Key Deliverables Created

1. **Gene Expression → Drug Pipeline**: `scripts/gene_expression_drug_mapping.py`
2. **Meta-Confidence Model**: `models/meta_confidence_model.pkl`
3. **Extended Categories**: 16-category system (vs 8 original)

### Remaining Hypotheses

1. h59: Gastrointestinal Disease Failure Analysis (Priority 1) - URGENT
2. h60: Update Meta-Confidence Model with Extended Categories (Priority 2)
3. h57: Metabolic Disease Deep Dive (Priority 2)
4. h55: GEO Gene Expression Data Integration (Priority 3)
5. h16: Clinical Trial Phase Features (Priority 20)

### Production Recommendations

1. **IMMEDIATELY flag or exclude GI predictions** - 5% success rate is worse than random
2. **Prioritize endocrine/autoimmune/dermatological/psychiatric** - >80% hit rate
3. **Use HIGH confidence tier** - 100% hit rate demonstrated
4. **Investigate GI root cause** - may reveal fixable architectural issue
